Abstract

Persistent human papillomavirus (HPV) infections have been identified as the main causes of cervical cancer. HPV vaccination has become the preferred option for the prevention of cervical cancer and pre-cancerous lesions. The effectiveness of vaccination could be indirectly reflected in the level of anti-HPV antibody. Therefore, immunogenicity analysis plays an important role in the clinical evaluation of HPV vaccines. Up to now, three HPV vaccines including Cervarix®, Gardasil® and Gardasil® 9 have been licensed in many countries, but a standard assay for assessing the immunogenicity of HPV vaccines has not been established. Currently, pseudovirion-based neutralization assay (PBNA), ELISA and competitive luminex immunoassay(cLIA) are the three major assays widely used in clinical trials of HPV vaccines. This study reviewed the traits of the three assays, the immunogenicity and durability of the three HPV vaccines, as well as the immune responses induced in different populations. Key words: Human papillomavirus; Vaccine; Immunogenicity; Cervical cancer

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.